True or False? While transposons need to move to reproduce and to distribute to new hosts, the process of transposition inevitably jeopardizes the host organism. True or False? Most transposons prefer DNA targets that are straight. True or False? Mammalian genomes such as the human genome have hundreds of thousands of LINEs, although fewer than 100 of these elements are thought to function autonomously.

answer 1 A cut-and-paste process allows DNA transposons to transfer from one genomic region to…

Answered: True or False? While transposons need…

True or False? While transposons need to move to reproduce and to distribute to new hosts, the process of transposition inevitably jeopardizes the host organism.

Human Heredity: Principles and Issues (MindTap Course List)

11th Edition

ISBN:9781305251052

Author:Michael Cummings

Publisher:Michael Cummings

Chapter15: Genomes And Genomics

Section15.1: Genomics And Personalized Medicine

Problem 1EG: Who Owns Your Genome? John Moore, an engineer working on the Alaska oil pipeline, was diagnosed in...

See similar textbooks

Similar questions

Many transposons move within a genome by replicative mechanisms . They therefore increase in copy number each time they transpose. Although individual transposition events are rare, many transposons are found in multiple copies in genomes. What do you suppose keeps the transposons from completely overrunning their hosts’ genomes?
True/False True or False? Transposon mutagenesis is useful for identifying essential genes in a cell. True or False? Transposons are found at various levels of complexity in bacteria. True or False? Transposons in eukaryotes are mechanistically different from bacterial transposons.
The technique of fluorescence in situ hybridization (FISH) is described. This is another method for examining sequence complexity within a genome. In this method, a DNA sequence, such as a particular gene sequence, can be detected within an intact chromosome by using a DNA probe that is complementary to the sequence.For example, let’s consider the β-globin gene, which isfound on human chromosome 11. A probe complementary to theβ-globin gene binds to that gene and shows up as a brightly colored spot on human chromosome 11. In this way, researchers can detectwhere the β-globin gene is located within a set of chromosomes. Becausethe β-globin gene is unique and because human cells are diploid(i.e., have two copies of each chromosome), a FISH experimentshows two bright spots per cell; the probe binds to each copy ofchromosome 11. What would you expect to see if you used thefollowing types of probes?A. A probe complementary to the Alu sequenceB. A probe complementary to a tandem array near…
Match each of the following to cis-acting or trans-acting. If you are in doubt, try drawing out a partial diploid! promoter sequence [Choose ] repressor protein [Choose ] operator [Choose ] CAP protein [Choose ] CAP binding site [Choose ]
A codon is a triplet of bases which codes for an amino acid. Exons are intervening sequence that are not spliced out during transcriptiona modification. RNA can never be double-stranded like DNA in both prokaryotes and eukaryotes. Alteration in BRCA-2 results to breast and ovarian cancer because of defect in the repair by homologous recombination. Write T if the statement is true and write F if the statement is false
Which of the following mobile genetic elements is a retrotransposon, making up about 10% of the human genome, but no longer codes for a functional gene product (and is therefore a “pseudogene”)? the LINE-1 element (repeated up to 50,000 times in the human genome) the DNA-only transposons known as “jumping genes” (in corn) the avocado sunblotch viroid the typical transposon found in a bacterial chromosome the Alu sequence (repeated up to 1,000,000 times in the human genome)
True or False? LINE elements encode functional transposition protein and thus can move autonomously in the human genome. True or False? Target-primed reverse transcription can mobilize information through an RNA intermediate.
Who Owns Your Genome? John Moore, an engineer working on the Alaska oil pipeline, was diagnosed in the mid-1970s with a rare and fatal form of cancer known as hairy cell leukemia. This disease causes overproduction of one type of white blood cell known as a T lymphocyte. Moore went to the UCLA Medical Center for treatment and was examined by Dr. David Golde, who recommended that Moores spleen be removed in an attempt to slow down or stop the cancer. For the next 8 years, John Moore returned to UCLA for checkups. Unknown to Moore, Dr. Golde and his research assistant applied for and received a patent on a cell line and products of that cell line derived from Moores spleen. The cell line, named Mo, produced a protein that stimulates the growth of two types of blood cells that are important in identifying and killing cancer cells. Arrangements were made with Genetics Institute, a small start-up company, and then Sandoz Pharmaceuticals, to develop the cell line and produce the growth-stimulating protein. Moore found out about the cell line and its related patents and filed suit to claim ownership of his cells and asked for a share of the profits derived from the sale of the cells or products from the cells. Eventually, the case went through three courts, and in July 1990n years after the case beganthe California Supreme Court ruled that patients such as John Moore do not have property rights over any cells or tissues removed from their bodies that are used later to develop drugs or other commercial products. This case was the first in the nation to establish a legal precedent for the commercial development and use of human tissue. The National Organ Transplant Act of 1984 prevents the sale of human organs. Current laws allow the sale of human tissues and cells but do not define ownership interests of donors. Questions originally raised in the Moore case remain largely unresolved in laws and public policy. These questions are being raised in many other cases as well. Who owns fetal and adult stem-cell lines established from donors, and who has ownership of and a commercial interest in diagnostic tests developed through cell and tissue donations by affected individuals? Who benefits from new genetic technologies based on molecules, cells, or tissues contributed by patients? Are these financial, medical, and ethical benefits being distributed fairly? What can be done to ensure that risks and benefits are distributed in an equitable manner? Gaps between technology, laws, and public policy developed with the advent of recombinant DNA technology in the 1970s, and in the intervening decades, those gaps have not been closed. These controversies are likely to continue as new developments in technology continue to outpace social consensus about their use. Should the physicians at UCLA have told Mr. Moore that his cells and its products were being commercially developed?
Who Owns Your Genome? John Moore, an engineer working on the Alaska oil pipeline, was diagnosed in the mid-1970s with a rare and fatal form of cancer known as hairy cell leukemia. This disease causes overproduction of one type of white blood cell known as a T lymphocyte. Moore went to the UCLA Medical Center for treatment and was examined by Dr. David Golde, who recommended that Moores spleen be removed in an attempt to slow down or stop the cancer. For the next 8 years, John Moore returned to UCLA for checkups. Unknown to Moore, Dr. Golde and his research assistant applied for and received a patent on a cell line and products of that cell line derived from Moores spleen. The cell line, named Mo, produced a protein that stimulates the growth of two types of blood cells that are important in identifying and killing cancer cells. Arrangements were made with Genetics Institute, a small start-up company, and then Sandoz Pharmaceuticals, to develop the cell line and produce the growth-stimulating protein. Moore found out about the cell line and its related patents and filed suit to claim ownership of his cells and asked for a share of the profits derived from the sale of the cells or products from the cells. Eventually, the case went through three courts, and in July 1990n years after the case beganthe California Supreme Court ruled that patients such as John Moore do not have property rights over any cells or tissues removed from their bodies that are used later to develop drugs or other commercial products. This case was the first in the nation to establish a legal precedent for the commercial development and use of human tissue. The National Organ Transplant Act of 1984 prevents the sale of human organs. Current laws allow the sale of human tissues and cells but do not define ownership interests of donors. Questions originally raised in the Moore case remain largely unresolved in laws and public policy. These questions are being raised in many other cases as well. Who owns fetal and adult stem-cell lines established from donors, and who has ownership of and a commercial interest in diagnostic tests developed through cell and tissue donations by affected individuals? Who benefits from new genetic technologies based on molecules, cells, or tissues contributed by patients? Are these financial, medical, and ethical benefits being distributed fairly? What can be done to ensure that risks and benefits are distributed in an equitable manner? Gaps between technology, laws, and public policy developed with the advent of recombinant DNA technology in the 1970s, and in the intervening decades, those gaps have not been closed. These controversies are likely to continue as new developments in technology continue to outpace social consensus about their use. Do you think that donors or patients who provide cells and/or tissues should retain ownership of their body parts or should share in any financial benefits that might derive from their use in research or commercial applications?
Viruses are a contributing factor in 10-20% of human cancers. Some viruses that contribute to human cancer do so as a result of certain steps in their replication cycle. Describe all the general steps of a viral replication cycle of a virus that could contribute to healthy cells turning cancerous. Which step(s) in particular could lead to cancer and how? Other viruses contribute to development of cancer in humans through expression of viral genes that mimic enhanced activity of certain normal human genes. What would you call the normal human gene? What would a likely function of the normal human gene be? What characteristic would the viral “mimic” gene promote in cancer cells? How would this benefit the virus?
Materials In order to determine the genetic material of a T2 phage, Alfred Hershey and Martha Chase conducted experiments using T2 phages that infected bacteria. In one treatment, they grew phages with radioactive sulfur. In another treatment, they grew phages with radioactive phosphorous. They allowed both types of phages to infect bacterial cells. After infection, they found that only bacteria infected with phages grown with radioactive phosphorous showed any radioactivity. Why did they use radioactive sulfur and phosphorous for this Updates Grades Members O Conferences DBQ Online experiment? * Newsela ormation O Sulfur is part of the DNA molecule but not part of a protein molecule. Biology Periods 1 and 2 Sulfur and phosphorous are some of the most reactive molecules and are easily ding periods school MP1, Highschool Highschool MP3, school MP4 traced. Sulfur and phosphorous are able to survive the centrifuge, a crucial component of the experiment. ion Phosphorous is part of the DNA…
During X inactivation, all but one gene get silenced on one X chromosome. Why does one gene escape the inactivation? A) That is the gene responsible for inactivating the others B) Two copies of that gene are needed in females, so both are active C) X inactivation is rarely complete, so occasionally one or two genes get activated by mistake D) That is the gene that encodes the methyltransferase needed to methylate the genome.